• News
  • SAN DIEGO
  • BioTech

Isis stock zig-zags on test results

The stock price at Isis Pharmaceuticals Inc. (Nasdaq: ISIS) wobbled sharply on Monday and Tuesday on the heels of its announcement of positive test results on its treatment for the hepatitis B virus.

Isis revealed on Monday that that its HBVRx compound produced reductions in all measured liver and serum viral markers of hepatitis B, using animal-based models of infection.

Gaetan Billioud, from the Scripps Research Institute, will unveil the specific data at the 49th annual meeting of the European Association for the Study of the Liver in London next month. In the meantime, Isis is currently evaluating testing HBVRx in a phase 1 study using healthy volunteers.

It was a positive development, but the stock has been on a roller coaster ride ever since. After the announcement was made Monday morning, Isis stock dipped sharply, regained the lost territory by mid-afternoon, rose more in after-hours trading but then dipped again on Tuesday morning so that by noon on Wall Street it was at $42.32, nearly a dollar lower than its level when the announcement was made.

In his “Mad Money” investment show on CNBC, analyst Jim Cramer warned investors not to immediately invest in the stock, because a number of short-sellers -- who had essentially bet on a decline -- were helping push the price down.

“It's a good company, but I wouldn't buy yet,” Cramer said, cautioning investors to wait for an "all clear signal" that the battle between short-sellers and long-term investors was over. “Watch for the stock to go down big ... and then reverse and ultimately go out higher. That's the sign to buy.”

In the meantime, Todd Campbell, president of Gundalow Advisors Wealth Management in New Hampshire, said there is more reason for buying Isis, suggesting that its proposed treatment for vision loss caused by diabetes be able to challenge vision-improvement treatments from Regeneron (Nasdaq: REGN) and Novartis (NYSE: NVS). He noted that Regneron's Eylea had $1.8 billion in sales last year, just two years after winning FDA approval, and sales of Novartis' Lucentis have hit more than $4 billion a year.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
44.62
  0.68  
+ 1.55%
1,703,078,000
77.8
37.38

Insider Trade Data

Date Insider Shares Type Value
10/02/2015 Parshall, B Lynne 12,436 Sell $506,747
10/02/2015 Parshall, B Lynne 12,436 Exchange $151,720
10/02/2015 Parshall, B Lynne 12,436 Sell $506,747
10/02/2015 Parshall, B Lynne 12,436 Exchange $151,720
07/06/2015 Crooke, Stanley T 12,350 Sell $707,457

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chairman, Chief Executive Officer, Founder, President

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
Subscribe Today!